Sernova Corp - Company Profile
Powered by 
All the data and insights you need on Sernova Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Sernova Corp Strategy Report
- Understand Sernova Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like environment for the long-term survival and function of insulin producing islets for the treatment of diabetes. Sernova uses proprietary local immune protection technologies that protect therapeutic cells within the Cell Pouch from the attack of immune system. Its major pipeline products include human donor islets, microencapsulated islets; microencapsulated stem cell derived cells; corrected patient cells; allograft immune protected cells; and autograft thyroid cells. The company’s product portfolio addresses metabolic diseases such as insulin dependent diabetes, thyroid problems, blood disorders such as hemophilia A and other diseases. Sernova is headquartered in London, Ontario, Canada.
Headquarters
Canada
Address
700 Collip Circle, Ste 114, London, Ontario, N6G4X8
Website
www.sernova.com
Telephone
1 519 8585126
Industry
Medical Equipment
Ticker Symbol & Exchange
SVA (TSE)
EPS
XYZ
Net Income (2022)
XYZ
-59.7%
(2022 vs 2021)
Market Cap*
$94.4M
* As of and is in US$
Sernova Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cell Pouch System | Cell Pouch System |
| Immune Protection Technology | |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into a research collaboration with AstraZeneca to evaluate the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells. |
| 2022 | Contracts/Agreements | In May, the company entered into a partnership with Evotec SE to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2. |
| 2020 | Contracts/Agreements | In August, the company entered into an agreement with University of Miami for the commercial rights therapeutic cell immune protection technologies. |
Competitor Comparison
| Key Parameters | Sernova Corp | AstraZeneca Plc | Sigilon Therapeutics Inc | Diamyd Medical AB | Alnara Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United Kingdom | United States of America | Sweden | United States of America |
| City | London | Cambridge | Cambridge | Stockholm | Boston |
| State/Province | Ontario | England | Massachusetts | - | Massachusetts |
| No. of Employees | - | 89,900 | 62 | 25 | - |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Brett Whalen | Chairman | Executive Board | 2023 | - |
| Cynthia Pussinen | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Philip M. Toleikis | Chief Technology Officer; Director | Executive Board | 2022 | - |
| Modestus Obochi, Ph.D | Chief Business Officer | Senior Management | 2023 | - |
| Nicholas J. Rossettos | Chief Financial Officer - Interim | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer